Condition
C. Diff. Infections
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 4 (1)
Trial Status
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT04626947Phase 4Terminated
Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
NCT04893239Phase 1CompletedPrimary
Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies
Showing all 2 trials